跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
WEGOVY - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
WEGOVY
Authorized
STANDARD
WEGOVY
Novo Nordisk Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
004a5a4b36c6b753
Company
Novo Nordisk Canada Inc
Type
Standard
Approval Details
Approval Id
004a5a4b36c6b753
Drug Approval Canada Name
WEGOVY
Product Name
WEGOVY
Status
Marketed
Status Date
2024-04-02
Original Market Date
2024-04-02
Din
02528517
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
68:20.06
Atc Original
A10BJ06 SEMAGLUTIDE
Atc Name
a 10 bj 06
Aig Number
0159870002
Company Name
Novo Nordisk Canada Inc
Company Address
101-2476 Argentia Road, Mississauga, Ontario, Canada, L5N 6M1
Active Ingredients
SEMAGLUTIDE
2 MG / 1.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
004a5a4b36c6b753
Type
Standard
Back to Health Canada Approvals